# NCT04214262 (NCT04214262)

> Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04214262
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8
- Interventions: Atezolizumab; Biospecimen Collection; Computed Tomography; Fludeoxyglucose F-18; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy
- Enrollment: 417
- Primary outcome: Overall Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04214262